Q4 2022 Earnings Estimate for Insulet Co. (NASDAQ:PODD) Issued By William Blair

Insulet Co. (NASDAQ:PODDGet Rating) – Analysts at William Blair lowered their Q4 2022 EPS estimates for Insulet in a note issued to investors on Monday, November 21st. William Blair analyst M. Kaczor now anticipates that the medical instruments supplier will earn $0.11 per share for the quarter, down from their prior estimate of $0.20. The consensus estimate for Insulet’s current full-year earnings is $0.98 per share. William Blair also issued estimates for Insulet’s Q3 2023 earnings at $0.28 EPS and Q4 2023 earnings at $0.48 EPS.

Other research analysts have also recently issued research reports about the stock. Raymond James upped their target price on shares of Insulet from $280.00 to $320.00 and gave the company an “outperform” rating in a research report on Friday, November 4th. BTIG Research upped their target price on shares of Insulet from $285.00 to $320.00 in a research report on Friday, November 4th. Canaccord Genuity Group upped their target price on shares of Insulet from $290.00 to $310.00 and gave the company a “buy” rating in a research report on Friday, November 4th. Piper Sandler raised shares of Insulet from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $235.00 to $340.00 in a research report on Friday, November 4th. Finally, Morgan Stanley increased their price target on shares of Insulet from $273.00 to $300.00 and gave the stock an “equal weight” rating in a research report on Friday, November 4th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $300.62.

Insulet Trading Down 0.3 %

Shares of PODD opened at $289.73 on Tuesday. The company has a current ratio of 3.98, a quick ratio of 3.00 and a debt-to-equity ratio of 3.22. Insulet has a 12-month low of $181.00 and a 12-month high of $320.00. The firm has a 50-day moving average price of $255.44 and a 200 day moving average price of $241.51. The firm has a market capitalization of $20.12 billion, a P/E ratio of 1,207.21 and a beta of 0.79.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 15,000 shares of the stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $231.80, for a total value of $3,477,000.00. Following the transaction, the director now directly owns 13,695 shares in the company, valued at $3,174,501. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Dan Manea sold 200 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $294.62, for a total transaction of $58,924.00. Following the transaction, the senior vice president now directly owns 3,158 shares in the company, valued at $930,409.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Shacey Petrovic sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $231.80, for a total transaction of $3,477,000.00. Following the transaction, the director now owns 13,695 shares in the company, valued at $3,174,501. The disclosure for this sale can be found here. Insiders have sold 28,858 shares of company stock worth $7,756,109 over the last three months. Insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Insulet

Hedge funds have recently modified their holdings of the business. SeaCrest Wealth Management LLC purchased a new position in Insulet in the 2nd quarter valued at $26,000. Institutional & Family Asset Management LLC grew its holdings in shares of Insulet by 261.3% during the 1st quarter. Institutional & Family Asset Management LLC now owns 112 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 81 shares during the period. Quent Capital LLC grew its holdings in shares of Insulet by 310.7% during the 1st quarter. Quent Capital LLC now owns 115 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 87 shares during the period. Wolff Wiese Magana LLC grew its holdings in shares of Insulet by 153.6% during the 1st quarter. Wolff Wiese Magana LLC now owns 142 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 86 shares during the period. Finally, Huntington National Bank grew its holdings in shares of Insulet by 448.4% during the 3rd quarter. Huntington National Bank now owns 170 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 139 shares during the period.

Insulet Company Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Read More

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.